Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15898815 | 0.86 | PTPN1 (0.46) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL4150382 | 0.83 | KCNH2 (0.45) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL14578440 | 0.83 | MTNR1A (0.48) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL15898858 | 0.80 | PTPN1 (0.47) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL177538 | 0.79 | MAOB (0.47) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL4452486 | 0.79 | PTPN1 (0.50) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL2090916 | 0.79 | PTPN1 (0.46) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL2656059 | 0.78 | ALDH1A1 (0.47) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL2092797 | 0.78 | PTPN1 (0.40) | PTPN1ALDH1A1HSD17B10KCNH2HTR1A | |
| SCHEMBL4143654 | 0.76 | MTNR1A (0.64) | ALDH1A1HTR2CMTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7235569-B2 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | TPH1, TPH2, HTR3A | PTPN1 2981/4885ALDH1A1 955/4885HSD17B10 3970/4885 |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | PTPN1 4607/4885ALDH1A1 828/4885HSD17B10 2942/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | PTPN1 4607/4885ALDH1A1 828/4885HSD17B10 2942/4885 |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | TPH1, TPH2, HTR4 | PTPN1 2579/4885ALDH1A1 909/4885HSD17B10 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.